Project Details


ABIRISK (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk), whose enrollment ended on 31st March 2016, is a large European project funded by the Innovative Medicines Initiative (IMI) and it aims to provide an integrated approach to investigate anti-drug antibody formation in JIA, adult rheumatoid arthritis and other conditions treated with biopharmaceuticals.

PRINTO managed this project as a sub-study of PharmaChild and succeeded to collect the biologic samples (Serum and RNA) of 147 children with juvenile idiopathic arthritis newly treated with adalimumab, etanercept or tocilizumab at start of therapy and at 4 follow-up visits during the first year of treatment, with an extra visit between month 15 and month 18 for a total of 6 study visits.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115303, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Key findings

European Federation of Pharmaceutical Industries and Associations (EFPIA), PRINTO, Anti-Biopharmaceutical Immunization
Effective start/end date1/01/151/01/17

Field of Science

  • 3.2 Clinical medicine


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.